Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells
2022 · Clinical Cancer Research · 16 citations
https://doi.org/10.1158/1078-0432.ccr-22-0761
F
Federica Galvagno
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
27
Papers
61
Citations
4
h-index
3
i10-index
Federica Galvagno is an academic researcher from Candiolo Cancer Institute. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immune Cell Function and Interaction & CAR-T cell therapy research. The author has an h-index of 4, co-authored 23 publications.
ORCID: 0000-0003-2245-6810Papers by this author
worksThe cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes
2025 · Cancer Immunology Immunotherapy · 1 citations
https://doi.org/10.1007/s00262-025-04141-w
Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation
2025 · Cancer Immunology Immunotherapy · 0 citations
https://doi.org/10.1007/s00262-025-04163-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat